Quantcast
Home / Opinions / Opinion Digest / New warning label excluded from Zometa trial

New warning label excluded from Zometa trial

A product liability plaintiff could not introduce evidence that the defendant added a new warning label to the osteoporosis drug that allegedly injured her husband, a U.S. District Court in New York has ruled in granting a motion in limine.